European bladder cancer market was valued at $1.6 billion in 2025 and is projected to reach $2.5 billion by 2035, growing at a CAGR of 4.6% during the forecast period (2026–2035). The European bladder cancer market is evolving rapidly, supported by rising disease awareness, structured screening pathways, and expanding access to advanced therapeutics across major EU economies. As healthcare systems focus on improving long-term management and cost efficiency, digital transformation is becoming a central pillar in oncology care delivery. Mobile health applications, remote patient monitoring platforms, AI-enabled diagnostic imaging systems, and digital pathology solutions are enhancing early detection, recurrence tracking, and treatment adherence. For instance, in April 2024, Huma Therapeutics and Merck KGaA, Darmstadt, Germany launched a bladder cancer treatment companion app in the UK to support patients and caregivers throughout their care journey. Developed in collaboration with healthcare professionals and patient organisations, the app provides treatment information, symptom tracking, and resources to enhance patient understanding and engagement.
Browse the full report description of “European Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other Rare Types) By Diagnosis Method (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Other) By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other), 2026–2035)” at https://www.omrglobal.com/industry-reports/european-bladder-cancer-market
Recent innovations in AI-powered diagnostics are transforming bladder cancer care by enhancing the precision, speed, and predictive capability of disease detection and risk stratification. Leading digital health companies are developing advanced computational pathology tools, predictive biomarker platforms, and machine-learning algorithms that support more individualized treatment decisions and improve clinical outcomes. For instance, in June 2025, Valar Labs announced that its CHAI (Computational Histology AI) biomarkers were validated in a multi-center study published in European Urology for predicting outcomes in high-grade Ta non-muscle invasive bladder cancer (NMIBC). The study demonstrated that the company’s Vesta platform accurately stratified recurrence and progression risk and outperformed current guideline-based risk models. The findings support the use of AI-driven pathology analysis to enable more precise, individualized treatment decisions in bladder cancer management. Collectively, these digital innovations are reinforcing clinical efficiency, optimizing resource allocation, and contributing to sustainable growth in the European bladder cancer market.
Market Updates and Regulatory Approvals
The European bladder cancer market is led by key companies such as AstraZeneca plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Pfizer Inc., among others. Major players are focusing on regulatory approvals, innovative therapies, and diagnostic advancements to strengthen market presence and address unmet clinical needs. Emphasis is placed on novel immunotherapies and next-generation diagnostic tools to improve patient monitoring, treatment outcomes, and early detection.
Market Coverage
Key questions addressed by the report.
European Bladder Cancer Market Report Segment
By Cancer Type
By Diagnosis Method
By Therapy
European Bladder Cancer Market Report Segment by Region
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/european-bladder-cancer-market